Du Puy, R. S.
Postmus, I.
Stott, D. J.
Blum, M. R.
Poortvliet, R. K. E.
Den Elzen, W. P. J.
Peeters, R. P.
van Munster, B. C.
Wolffenbuttel, B. H. R.
Westendorp, R. G. J.
Kearney, P. M.
Ford, I.
Kean, S.
Messow, C. M.
Watt, T.
Jukema, J. W.
Dekkers, O. M.
Smit, J. W. A.
Rodondi, N.
Gussekloo, J.
Mooijaart, S. P. http://orcid.org/0000-0003-3106-3568
Funding for this research was provided by:
ZonMw (627001001)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030-150025 & 320030-172676)
Article History
Received: 3 May 2018
Accepted: 3 August 2018
First Online: 19 September 2018
Ethics approval and consent to participate
: For the Netherlands site the study was approved by the Medical Ethical Committee on Research Involving Human Subjects (CCMO). For the Switzerland site the study was approved by the Bern ethical board and by the Swiss competent authority for drugs (Swissmedic). All participants provided written informed consent for both the screening and the participation phase (Additional files InternalRef removed and InternalRef removed).
: Not applicable.
: ZonMw and the Swiss National Science Foundation, as the funder, had no role in the design and conduct of the study nor in the preparation, review or approval of the manuscript. Merck KGaA provided the study medication and matching placebos without recompense. Merck KGaA was not involved in the design, funding or execution of the study or manuscript. The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.